Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 20, 2017, Pages E4030-E4039

  Schwartzman, Omer ^a,b,c   Savino, Angela Maria ^a,b   Gombert, Michael ^d   Palmi, Chiara ^e   Cario, Gunnar ^f   Schrappe, Martin ^f   Eckert, Cornelia ^g   Stackelberg, Arend Von ^g   Huang, Jin Yan ^h   Hameiri Grossman, Michal ^b,i   Avigad, Smadar ^b,i   Kronnie, Geertruy Te ^j   Geron, Ifat ^a,b   Birger, Yehudit ^a,b   Rein, Avigail ^a,b   Zarfati, Giulia ^a,b   Fischer, Ute ^d   Mukamel, Zohar ^c   Stanulla, Martin ^k   Biondi, Andrea ^d   Cazzaniga, Giovanni ^d   Vetere, Amedeo ^l,m   Wagner, Bridget K ^l,m   Chen, Zhu ^h   Chen, Sai Juan ^h   Tanay, Amos ^c   Borkhardt, Arndt ^d   Izraeli, Shai ^a,b   more..

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e UNIVERSITY OF MILANO BICOCCA   (Italy)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

ⁱ SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^j UNIVERSITY OF PADOVA   (Italy)

^k HANNOVER MEDICAL SCHOOL   (Germany)

^l BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^m HOWARD HUGHES MEDICAL INSTITUTE   (United States)

more..

Author keywords

Acute lymphoblastic leukemia; CRLF2; Down syndrome; JAK STAT signaling; USP9X

Indexed keywords

CD135 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DEUBIQUITINASE; INTERLEUKIN 7 RECEPTOR; JANUS KINASE; JANUS KINASE 1; JANUS KINASE 2; K RAS PROTEIN; MUTL PROTEIN HOMOLOG 1; PROTEIN MSH6; PROTEIN P53; RUXOLITINIB; STAT PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR PAX5; TRANSCRIPTION FACTOR RUNX1; CRLF2 PROTEIN, HUMAN; CYTOKINE RECEPTOR; UBIQUITIN THIOLESTERASE; USP9X PROTEIN, HUMAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER DIAGNOSIS; CHILD; COPY NUMBER VARIATION; DOWN SYNDROME; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LOW DRUG DOSE; MOLECULARLY TARGETED THERAPY; ONCOGENE N RAS; PATHOGENESIS; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SOMATIC MUTATION; THERAPY EFFECT; WHOLE EXOME SEQUENCING; ADOLESCENT; COMPLICATION; FEMALE; GENETICS; MALE; METABOLISM; MUTATION; PRESCHOOL CHILD; RECURRENT DISEASE; TUMOR CELL LINE; YOUNG ADULT;

ADOLESCENT; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; DOWN SYNDROME; FEMALE; HUMANS; JANUS KINASES; MALE; MUTATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTORS, CYTOKINE; RECURRENCE; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; UBIQUITIN THIOLESTERASE; YOUNG ADULT;

EID: 85019941813     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1702489114     Document Type: Article

References (78)

1. Hasle H (2001) Pattern of malignant disorders in individuals with Down's syndrome. Lancet Oncol 2:429-436.
2. Buitenkamp TD, et al. (2014) Acute lymphoblastic leukemia in children with Down syndrome: A retrospective analysis from the Ponte di Legno study group. Blood 123: 70-77.
3. Hertzberg L, et al. (2010) Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: A report from the International BFM Study Group. Blood 115: 1006-1017.
4. Izraeli S (2016) The acute lymphoblastic leukemia of Down syndrome-genetics and pathogenesis. Eur J Med Genet 59:158-161.
5. Mullighan CG, et al. (2009) Rearrangement of CRLF2 in B-progenitor-and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet 41:1243-1246.
6. Russell LJ, et al. (2009) Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood 114:2688-2698.
7. Tal N, Shochat C, Geron I, Bercovich D, Izraeli S (2014) Interleukin 7 and thymic stromal lymphopoietin: From immunity to leukemia. Cell Mol Life Sci 71:365-378.
8. Shochat C, et al. (2011) Gain-of-function mutations in interleukin-7 receptor- (IL7R) in childhood acute lymphoblastic leukemias. J Exp Med 208:901-908.
9. Bercovich D, et al. (2008) Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 372:1484-1492.
10. Nikolaev SI, et al. (2014) Frequent cases of RAS-mutated Down syndrome acute lymphoblastic leukaemia lack JAK2 mutations. Nat Commun 5:4654.
11. Roberts KG, et al. (2014) Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 371:1005-1015.
12. Izraeli S (2014) Beyond Philadelphia: 'Ph-like' B cell precursor acute lymphoblastic leukemias-Diagnostic challenges and therapeutic promises. Curr Opin Hematol 21: 289-296.
13. Palmi C, et al. (2016) CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia. Oncotarget 7:59260-59272.
14. Ge Z, et al. (2016) High CRLF2 expression associates with IKZF1 dysfunction in adult acute lymphoblastic leukemia without CRLF2 rearrangement. Oncotarget 7:49722-49732.
15. van der Veer A, et al. (2013) Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood 122:2622-2629.
16. Palmi C, et al. (2012) Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 overexpression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia. Leukemia 26:2245-2253.
17. Moorman AV, et al. (2012) IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia. J Clin Oncol 30:3100-3108.
18. Chen IM, et al. (2012) Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: A Children's Oncology Group study. Blood 119:3512-3522.
19. Cario G, et al. (2010) Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. Blood 115:5393-5397.
20. Morak M, et al. (2012) Small sizes and indolent evolutionary dynamics challenge the potential role of P2RY8-CRLF2-harboring clones as main relapse-driving force in childhood ALL. Blood 120:5134-5142.
21. Vesely C, et al. (2017) Genomic and transcriptional landscape of P2RY8-CRLF2-positive childhood acute lymphoblastic leukemia. Leukemia, 10.1038/leu.2016.365.
22. Kivioja T, et al. (2011) Counting absolute numbers of molecules using unique molecular identifiers. Nat Methods 9:72-74.
23. Paulsson K, et al. (2015) The genomic landscape of high hyperdiploid childhood acute lymphoblastic leukemia. Nat Genet 47:672-676.
24. Alexandrov LB, et al.; Australian Pancreatic Cancer Genome Initiative; ICGC Breast Cancer Consortium; ICGC MMML-Seq Consortium; ICGC PedBrain (2013) Signatures of mutational processes in human cancer. Nature 500:415-421.
25. Oshima K, et al. (2016) Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia. Proc Natl Acad Sci USA 113: 11306-11311.
26. Malinowska-Ozdowy K, et al. (2015) KRAS and CREBBP mutations: A relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia. Leukemia 29:1656-1667.
27. Loudin MG, et al. (2011) Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles. Leukemia 25:1555-1563.
28. Russell LJ, et al. (2016) Characterisation of the genomic landscape of CRLF2-rearranged acute lymphoblastic leukemia. Genes Chromosomes Cancer 56:363-372.
29. Shaham L, Binder V, Gefen N, Borkhardt A, Izraeli S (2012) MiR-125 in normal and malignant hematopoiesis. Leukemia 26:2011-2018.
30. Mar BG, et al. (2014) Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. Nat Commun 5:3469.
31. Adzhubei I, Jordan DM, Sunyaev SR (2013) Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protoc Hum Genet Chapter 7:Unit7 20.
32. Auclair J, et al. (2006) Systematic mRNA analysis for the effect of MLH1 and MSH2 missense and silent mutations on aberrant splicing. Hum Mutat 27:145-154.
33. Li F, et al. (2013) The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutS-. Cell 153:590-600.
34. Tzoneva G, et al. (2013) Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nat Med 19:368-371.
35. Meyer JA, et al. (2013) Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat Genet 45:290-294.
36. Shochat C, et al. (2014) Novel activating mutations lacking cysteine in type I cytokine receptors in acute lymphoblastic leukemia. Blood 124:106-110.
37. Schwickart M, et al. (2010) Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 463:103-107.
38. Wang S, et al. (2014) Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer. Proc Natl Acad Sci USA 111:4251-4256.
39. Yang B, et al. (2016) Deubiquitinase USP9X deubiquitinates -catenin and promotes high grade glioma cell growth. Oncotarget 7:79515-79525.
40. Zhou M, et al. (2015) Targeting of the deubiquitinase USP9X attenuates B-cell acute lymphoblastic leukemia cell survival and overcomes glucocorticoid resistance. Biochem Biophys Res Commun 459:333-339.
41. Liu Y-F, et al. Genomic profiling of adult and pediatric B-cell acute lymphoblastic leukemia. EBioMedicine 8:173-83.
42. Yasuda T, et al. (2016) Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults. Nat Genet 48:569-574.
43. Lilljebj-rn H, et al. (2016) Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia. Nat Commun 7:11790.
44. Ma X, et al. (2015) Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. Nat Commun 6:6604.
45. Zhou X, et al. (2016) Exploring genomic alteration in pediatric cancer using ProteinPaint. Nat Genet 48:4-6.
46. Chou DH, et al. (2015) Kinase-independent small-molecule inhibition of JAK-STAT signaling. J Am Chem Soc 137:7929-7934.
47. Shojaee S, et al. (2015) Erk negative feedback control enables pre-B cell transformation and represents a therapeutic target in acute lymphoblastic leukemia. Cancer Cell 28:114-128.
48. Grundschober E, et al. (2014) Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2. Leukemia 28:1918-1922.
49. Frishman-Levy L, et al. (2015) Central nervous system acute lymphoblastic leukemia: Role of natural killer cells. Blood 125:3420-3431.
50. Dixon ZA, et al. (2016) CREBBP knockdown enhances RAS/RAF/MEK/ERK signalling in Ras pathway mutated acute lymphoblastic leukaemia but does not modulate chemotherapeutic response. Haematologica 102:736-745.
51. Engel K, et al. (2016) USP9X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive B-cell lymphoma. EMBO Mol Med 8:851-862.
52. Vucic D, Dixit VM, Wertz IE (2011) Ubiquitylation in apoptosis: A post-translational modification at the edge of life and death. Nat Rev Mol Cell Biol 12:439-452.
53. P-rez-Mancera PA, et al.; Australian Pancreatic Cancer Genome Initiative (2012) The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature 486: 266-270.
54. Reijnders MR, et al.; DDD Study (2016) De novo loss-of-function mutations in USP9X cause a female-specific recognizable syndrome with developmental delay and congenital malformations. Am J Hum Genet 98:373-381.
55. Naik E, Dixit VM (2016) Usp9X is required for lymphocyte activation and homeostasis through its control of ZAP70 ubiquitination and PKC- kinase activity. J Immunol 196: 3438-3451.
56. Naik E, et al. (2014) Regulation of proximal T cell receptor signaling and tolerance induction by deubiquitinase Usp9X. J Exp Med 211:1947-1955.
57. Chen Z, et al. (2015) Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. Nature 521:357-361.
58. Cario G, et al. (2014) High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica 99:103-110.
59. Irving JA, et al. (2016) Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia. Blood 128:911-922.
60. Trentin L, et al. (2016) Deciphering KRAS and NRAS mutated clone dynamics in MLLAF4 paediatric leukaemia by ultra deep sequencing analysis. Sci Rep 6:34449.
61. Cheok MH, et al. (2003) Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nat Genet 34:85-90.
62. Collins-Underwood JR, Mullighan CG (2010) Genomic profiling of high-risk acute lymphoblastic leukemia. Leukemia 24:1676-1685.
63. Ebinger S, et al. (2016) Characterization of rare, dormant, and therapy-resistant cells in acute lymphoblastic leukemia. Cancer Cell 30:849-862.
64. Schwickert TA, et al. (2014) Stage-specific control of early B cell development by the transcription factor Ikaros. Nat Immunol 15:283-293.
65. Joshi I, et al. (2014) Loss of Ikaros DNA-binding function confers integrin-dependent survival on pre-B cells and progression to acute lymphoblastic leukemia. Nat Immunol 15:294-304.
66. Song C, et al. (2015) Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia. Blood 126: 1813-1822.
67. Francis OL, et al. (2016) A novel xenograft model to study the role of TSLP-induced CRLF2 signals in normal and malignant human B lymphopoiesis. Haematologica 101: 417-426.
68. Gauvreau GM, et al. (2014) Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med 370:2102-2110.
69. Vetter T, et al. (2016) Blockade of thymic stromal lymphopoietin (TSLP) receptor inhibits TSLP-driven proliferation and signalling in lymphoblasts from a subset of B-precursor ALL patients. Leuk Res 40:38-43.
70. Qin H, et al. (2015) Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein. Blood 126:629-639.
71. Cibulskis K, et al. (2013) Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 31:213-219.
72. Magi A, et al. (2013) EXCAVATOR: Detecting copy number variants from wholeexome sequencing data. Genome Biol 14:R120.
73. Sanjana NE, Shalem O, Zhang F (2014) Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods 11:783-784.
74. Van der Auwera GA, et al. (2013) From FastQ data to high confidence variant calls: The Genome Analysis Toolkit best practices pipeline. Curr Protoc Bioinformatics 43: 11.10.1-11.10.33.
75. Lek M, et al.; Exome Aggregation Consortium (2016) Analysis of protein-coding genetic variation in 60,706 humans. Nature 536:285-291.
76. Mermel CH, et al. (2011) GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol 12:R41.
77. Carter SL, et al. (2012) Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol 30:413-421.
78. Tiscornia G, Singer O, Verma IM (2006) Production and purification of lentiviral vectors. Nat Protoc 1:241-245.